Microbes and Alzheimer's Disease

Manuscript Number: 

16-0152

Author(s): 
Brian J. Balin, Melvyn J. Ball, Elaine L. Bearer, Heiko Braak, Maria J. Bullido, Chris Carter, Mario Clerici, S. Louise Cosby, Kelly Del Tredici, Hugh Field, Tamàs Fülöp Jr., Claudio Grassi, W. Sue T. Griffin, Jürgen Haas, Alan P. Hudson, Ruth F. Itzhaki, Angela R. Kamer, Douglas Kell, Richard Lathe, Luc Letenneur, Federico Licastro, Hugo Lövheim, Roberta Mancuso, Judith Miklossy, Carola Otth, Anna Teresa Palamara, George Perry, Christopher Preston, Resia Pretorius, Timo E. Strandberg, Naji Tabet, Simon D. Taylor-Robinson, Judith A. Whittum-Hudson

Disclosures

Brian J. Balin

  • Nothing to Disclose

Melvyn J. Ball

  • Nothing to Disclose

Elaine L. Bearer

  • Nothing to Disclose

Heiko Braak

  • Nothing to Disclose

Maria J. Bullido

  • Nothing to Disclose

Chris Carter

  • Nothing to Disclose

Mario Clerici

  • Nothing to Disclose

S. Louise Cosby

  • Nothing to Disclose

Kelly Del Tredici

  • Nothing to Disclose

Hugh Field

  • Nothing to Disclose

Tamàs Fülöp Jr.

  • Nothing to Disclose

Claudio Grassi

  • Nothing to Disclose

W. Sue T. Griffin

  • Nothing to Disclose

Jürgen Haas

  • Nothing to Disclose

Alan P. Hudson

  • Nothing to Disclose

Ruth F. Itzhaki

  • Nothing to Disclose

Angela R. Kamer

  • Nothing to Disclose

Douglas Kell

  • Nothing to Disclose

Richard Lathe

  • Nothing to Disclose

Luc Letenneur

  • Nothing to Disclose

Federico Licastro

  • Nothing to Disclose

Hugo Lövheim

  • Nothing to Disclose

Roberta Mancuso

  • Nothing to Disclose

Judith Miklossy

  • Nothing to Disclose

Carola Otth

  • Nothing to Disclose

Anna Teresa Palamara

  • Nothing to Disclose

George Perry

  • Nothing to Disclose

Christopher Preston

  • Nothing to Disclose

Resia Pretorius

  • Nothing to Disclose

Timo E. Strandberg

  • Consulting Fees:
    Occasionally, minor amount, several companies during the past few years. Not related to the article topic
    Equity:
    OrionPharma, listed company, minor amount
    Lecture Fees:
    Occasional lectures, various companies. Not related to the article topic

Naji Tabet

  • Consulting Fees:
    Advising Eli Lilly (Two advisory board meetings a year)and Roche (one advisory board meeting a year) on Dementia issues.
    Grants
    • Agency: 
      Avid Radiopharmaceuticals supporting a pilot study I am carrying out in Dementia.
      Dates: 
      2015

Simon D. Taylor-Robinson

  • Nothing to Disclose

Judith A. Whittum-Hudson

  • Nothing to Disclose